Pfizer

Valuation Analysis

About the Company

Pfizer en bref

Pfizer (PFE) is currently trading at 22,04 € with a market capitalization of 125,6 Md €. The trailing P/E ratio stands at 19.28x, with a forward P/E of 8.93x. The 52-week range spans from 20,17 € to 25,09 €; the current price is 12.1% below the yearly high. Year-over-year revenue growth stands at +5.4%. The net profit margin stands at 11.83%.

💰 Dividende

Pfizer pays an annual dividend of 1,50 € per share, representing a yield of 6.81%. The payout ratio stands at 131.3%. The elevated payout ratio reflects a mature dividend policy.

📊 Avis des analystes

27 analystes évaluent Pfizer (PFE) au consensus : Acheter. L'objectif de cours moyen est de 25,47 €, soit un potentiel de +15.56% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,94 € à 31,42 €.

Pfizer : la thèse d'investissement en détail

Pfizer (PFE) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 74.8%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 15.56% upside from current levels — analyst sentiment is firmly constructive.

Valorisation en contexte

At a PEG of 13.77, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 7.87x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

Signal Smart Money

On the institutional side, Pfizer appears in the disclosed holdings of Burry. Smart-money managers track positioning, fundamentals and competitive dynamics with research budgets few retail investors can match — when several converge on the same name, it is rarely random. That doesn't mean blind copying makes sense, but it does raise the bar for the bear case.

À surveiller

• The forward P/E of 8.93x is meaningfully below the trailing 19.28x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Pfizer?

Compare top-rated brokers — low fees, trusted providers, fully regulated.